Physician profile
William G Ferrell
NPI 1740212562
$22,824.98
in general payments reported to CMS, 2019-2025
82 companies · $4,995 in 2025
The $4,995 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,421 · 2020: $865 · 2021: $2,839 · 2022: $2,970 · 2023: $3,458 · 2024: $4,277 · 2025: $4,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,489.05 |
| Education | $239.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,952.79 | 2021-2025 | |
| Ucb, INC. | $1,435.21 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,268.41 | 2019-2025 | |
| Amgen INC. | $1,228.43 | 2019-2025 | Uplizna, Aimovig |
| Teva Pharmaceuticals USA, INC. | $1,049.64 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Genzyme Corporation | $997.46 | 2019-2023 | |
| Tg Therapeutics, INC. | $922.63 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $918.39 | 2019-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $763.31 | 2019-2025 | Vyepti |
| Pfizer INC. | $631.73 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $608.31 | 2019-2025 | Ingrezza, Ongentys |
| Neurelis, INC. | $607.09 | 2020-2025 | Valtoco |
| Genentech USA, INC. | $552.68 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Eisai INC. | $543.74 | 2019-2025 | |
| Biogen, INC. | $536.63 | 2019-2025 | Tysabri, Vumerity, Leqembi |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.